Clinical Trial

An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 6, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
A single-center, open-label, non-randomized controlled exploratory study is conducted in the Xuanwu Hospital Capital Medical University to evaluate the efficacy and safety of FCN-159 in patients with brain arteriovenous malformations (BAVM), aiming to overcome the current clinical challenges caused by the lack of available drugs for this disease.
Trial Details
NCT Number NCT06913725
Lead Sponsor Xuanwu Hospital, Beijing
Collaborators: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions Brain Arteriovenous Malformations
Enrollment 10 participants
Start Date 2025-02-24
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-06